Cargando…

Recommendations and management of hyperglycaemia in pregnancy during COVID-19 pandemic in Italy

Many specialists use the remote management of people with chronic disease as diabetes, but structured management protocols have not been developed yet. The COVID-19 pandemic has given a big boost to the use of telemedicine, as it allows to maintain the physical distance, essential to the containment...

Descripción completa

Detalles Bibliográficos
Autores principales: Torlone, Elisabetta, Sculli, Maria Angela, Bonomo, Matteo, Di Benedetto, Antonino, Di Cianni, Graziano, Festa, Camilla, Formoso, Gloria, Lapolla, Annunziata, Mannino, Domenico, Napoli, Angela, Scavini, Marina, Succurro, Elena, Vitacolonna, Ester, Sciacca, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375279/
https://www.ncbi.nlm.nih.gov/pubmed/32710999
http://dx.doi.org/10.1016/j.diabres.2020.108345
Descripción
Sumario:Many specialists use the remote management of people with chronic disease as diabetes, but structured management protocols have not been developed yet. The COVID-19 pandemic has given a big boost to the use of telemedicine, as it allows to maintain the physical distance, essential to the containment of contagion having regular health contact. Encouraging results related to the use of telemedicine in women with hyperglycaemia in pregnancy, have been recently published. It is well known that hyperglycaemia alters the immune response to infections, that inflammation, in turn, worsens glycaemic control and that any form of hyperglycaemia in pregnancy (HIP) has effects not only on the mother but also on development of the foetus. Therefore, the Italian Diabetes and Pregnancy Study Group, together with a group of experts, developed these recommendations in order to guide physicians in the management of HIP, providing specific diagnostic, therapeutic and assistance pathways (PDTAs) for the COVID-19 emergency. Three detailed PDTAs were developed, for type 1, type 2 and gestational diabetes.